Engineering of structural and functional properties of nanotherapeutics and nanodiagnostics for intranasal brain targeting in Alzheimer's

Hinge, Nikita Subhash; Kathuria, Himanshu; Pandey, Murali Monohar

doi:10.1016/j.apmt.2021.101303

Cited by 15 publications

(10 citation statements)

References 345 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another promising option is using nano-scale carriers for drugs, whose effectiveness in central nervous system disorders has been reviewed recently [ 113 , 114 , 115 , 116 , 117 , 118 ]. The application of nanocarriers to treat AD has also recently been reviewed [ 119 ].…”

Section: Drug Discovery and Development For Dementiamentioning

confidence: 99%

Drug Discovery and Development Targeting Dementia

et al. 2023

View full text Add to dashboard Cite

Dementia, most often associated with neurodegenerative diseases, affects millions of people worldwide, predominantly the elderly. Unfortunately, no treatment is still available. Therefore, there is an urgent need to address this situation. This review presents the state of the art of drug discovery and developments in targeting dementia. Several approaches are discussed, such as drug repurposing, the use of small molecules, and phosphodiesterase inhibitors. Furthermore, the review also provides insights into clinical trials of these molecules. Emphasis has been placed on small molecules and multi-target-directed ligands, as well as disease-modifying therapies. Finally, attention is drawn to the possibilities of applications of nanotechnology in managing dementia.

show abstract

Section: Drug Discovery and Development For Dementiamentioning

confidence: 99%

Drug Discovery and Development Targeting Dementia

et al. 2023

View full text Add to dashboard Cite

show abstract

“…[150] Recently, therapeutic activities of various forms of lectin-modified NPs with IN delivery method have been investigated. [151][152][153][154] Salem et al (2019) developed the lectin-functionalized NPs loaded with resveratrol, which showed highly effective potency to treat AD. These nanocomposites also displayed optimal brain penetration, when administered via IN.…”

Section: Lectin-modified Npsmentioning

confidence: 99%

Intranasal Delivery of Functionalized Polymeric Nanomaterials to the Brain

Zha

Wong

All

2022

Adv Healthcare Materials

View full text Add to dashboard Cite

Intravenous delivery of nanomaterials containing therapeutic agents and various cargos for treating neurological disorders is often constrained by low delivery efficacy due to difficulties in passing the blood-brain barrier (BBB). Nanoparticles (NPs) administered intranasally can move along olfactory and trigeminal nerves so that they do not need to pass through the BBB, allowing non-invasive, direct access to selective neural pathways within the brain. Hence, intranasal (IN) administration of NPs can effectively deliver drugs and genes into targeted regions of the brain, holding potential for efficacious disease treatment in the central nervous system (CNS). In this review, current methods for delivering conjugated NPs to the brain are primarily discussed. Distinctive potential mechanisms of therapeutic nanocomposites delivered via IN pathways to the brain are then discussed. Recent progress in developing functional NPs for applications in multimodal bioimaging, drug delivery, diagnostics, and therapeutics is also reviewed. This review is then concluded by discussing existing challenges, new directions, and future perspectives in IN delivery of nanomaterials.

show abstract

“…Despite the several successes that have been demonstrated with surgeries and highly evasive techniques, their clinical acceptance is limited due to varying concerns about their long-term benefit, owing to the potential damage to the brain barrier. As a suitable alternative for halting or reversing neurodegeneration, nanotherapeutics with the potential to cross the BBB (without damage to the barrier) have been proposed and demonstrated in many cases [4,5]. Nanotherapeutic use is gaining traction due to the several benefits compared to conventional dosage forms [6].…”

Section: Introductionmentioning

confidence: 99%

A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics

Lamptey

Chaulagain

Trivedi

et al. 2022

IJMS

274

View full text Add to dashboard Cite

Neurodegenerative disorders are primarily characterized by neuron loss. The most common neurodegenerative disorders include Alzheimer’s and Parkinson’s disease. Although there are several medicines currently approved for managing neurodegenerative disorders, a large majority of them only help with associated symptoms. This lack of pathogenesis-targeting therapies is primarily due to the restrictive effects of the blood–brain barrier (BBB), which keeps close to 99% of all “foreign substances” out of the brain. Since their discovery, nanoparticles have been successfully used for targeted delivery into many organs, including the brain. This review briefly describes the pathophysiology of Alzheimer’s, Parkinson’s disease, and amyotrophic lateral sclerosis, and their current management approaches. We then highlight the major challenges of brain-drug delivery, followed by the role of nanotherapeutics for the diagnosis and treatment of various neurological disorders.

show abstract

Engineering of structural and functional properties of nanotherapeutics and nanodiagnostics for intranasal brain targeting in Alzheimer's

Cited by 15 publications

References 345 publications

Drug Discovery and Development Targeting Dementia

Drug Discovery and Development Targeting Dementia

Intranasal Delivery of Functionalized Polymeric Nanomaterials to the Brain

A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics

Contact Info

Product

Resources

About